Skip to main content
TipRanks
Go Ultimate75% OFF

Xeris Pharmaceuticals (0A8E) Share Price & Analysis

0 Followers

0A8E Stock Chart & Stats

$16.73$0.12(0.69%)
At close: 4:30 PM GMT
$7.5$10$12.5$15Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$16.41 - $16.87
52-Week Range
$5.26 - $16.95
Previous Close
$16.61
Volume
N/A
Average Volume (3M)
6,146
Market Cap
$3.07B
Enterprise Value
$1.91B
Total Cash (Recent Filing)
$131.08M
Total Debt (Recent Filing)
$226.07M
Price to Earnings (P/E)
―
Beta
0.96
Next Earnings
Mar 10, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Accelerating Revenue Growth

Strong product demand is translating into substantial revenue growth, while the raised 2026 outlook indicates management sees momentum continuing beyond a single quarter. This scale can support greater commercial investment and improve operating leverage as the portfolio expands.

Strong Cash Generation

Positive and growing free cash flow gives Xeris internal funding for commercial expansion, evidence generation, and XP-8121 development. If sustained, this cash generation can reduce reliance on external financing and provide greater flexibility in allocating capital across growth opportunities.

Long-Dated Intellectual Property

Patent protection extending through at least 2043 can preserve KEVEYIS commercial exclusivity and support revenue visibility in a specialty indication. Longer protection also gives Xeris more time to invest in patient identification and support while defending the product from generic competition.

Bears Say

Elevated Balance Sheet Leverage

High leverage remains a material constraint even as equity has improved from prior negative levels. Debt substantially exceeds the equity base, which can limit financial flexibility, increase sensitivity to any slowdown in growth, and restrict the resources available for sustained investment.

GAAP Profitability Is Not Yet Durable

The slight TTM net loss shows that improved operating performance has not yet translated into consistently positive bottom-line earnings. Until profitability becomes durable, results remain more sensitive to operating costs and non-operating items, weakening the reliability of shareholder returns.

Rising Commercial Expenses

Higher commercial and personnel expenses are supporting expansion but create execution risk if revenue growth does not absorb the added cost base. The increased SG&A outlook could restrain operating-margin improvement and make sustained profitability harder while Xeris scales its commercial platform.

Xeris Pharmaceuticals News

0A8E FAQ

What was Xeris Pharmaceuticals’s price range in the past 12 months?
Xeris Pharmaceuticals lowest share price was $5.26 and its highest was $16.95 in the past 12 months.
What is Xeris Pharmaceuticals’s market cap?
Xeris Pharmaceuticals’s market cap is $3.07B.
When is Xeris Pharmaceuticals’s upcoming earnings report date?
Xeris Pharmaceuticals’s next earnings report is estimated for Mar 10, 2027 (not yet confirmed), which is in 112 days.
How were Xeris Pharmaceuticals’s earnings last quarter?
Xeris Pharmaceuticals released its earnings results on Nov 05, 2026. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.032 by $0.028.
Is Xeris Pharmaceuticals overvalued?
According to Wall Street analysts Xeris Pharmaceuticals’s price is currently Undervalued.
Does Xeris Pharmaceuticals pay dividends?
Xeris Pharmaceuticals does not currently pay dividends.
What is Xeris Pharmaceuticals’s EPS estimate?
Xeris Pharmaceuticals’s EPS estimate is 0.07.
How many shares outstanding does Xeris Pharmaceuticals have?
Xeris Pharmaceuticals has 182,700,040 shares outstanding.
What happened to Xeris Pharmaceuticals’s price movement after its last earnings report?
Xeris Pharmaceuticals reported an EPS of $0.06 in its last earnings report, beating expectations of $0.032. Following the earnings report the stock price went up 22.861%.
Which hedge fund is a major shareholder of Xeris Pharmaceuticals?
Hedge funds hold Xeris Pharmaceuticals shares: the largest hedge-fund position in Xeris Pharmaceuticals is 1,089,706,902 shares, and hedge funds increased their holdings by 6.1K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology